BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bedimo R, Abodunde O. Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. Curr HIV/AIDS Rep. 2016;13:328-339. [PMID: 27595755 DOI: 10.1007/s11904-016-0333-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Shelton BA, Berdahl G, Sawinski D, Linas BP, Reese PP, Mustian MN, Reed RD, MacLennan PA, Locke JE. Optimal timing of hepatitis C treatment among HIV/HCV coinfected ESRD patients: Pre- vs posttransplant. Am J Transplant 2019;19:1806-19. [PMID: 30589503 DOI: 10.1111/ajt.15239] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
2 Poliwczak AR, Białkowska J, Woźny J, Koziróg M, Bała A, Jabłkowski M. Cardiovascular risk assessment by electrocardiographic Holter monitoring in patients with chronic hepatitis C. Arch Med Sci 2020;16:1031-9. [PMID: 32863991 DOI: 10.5114/aoms.2020.96600] [Reference Citation Analysis]
3 Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART. Viruses 2019;11:E200. [PMID: 30818749 DOI: 10.3390/v11030200] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 43.0] [Reference Citation Analysis]
4 Meissner EG. Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. Curr Opin Gastroenterol 2017;33:120-7. [PMID: 28234770 DOI: 10.1097/MOG.0000000000000347] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
5 Osibogun O, Ogunmoroti O, Michos ED, Spatz ES, Olubajo B, Nasir K, Maziak W. A systematic review of the associations between HIV/HCV coinfection and biomarkers of cardiovascular disease. Rev Med Virol 2018;28. [PMID: 29135056 DOI: 10.1002/rmv.1953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Zhao XC, Ju B, Wei N, Ding J, Meng FJ, Zhao HG. Severe hyperlipemia-induced pseudoerythrocytosis - Implication for misdiagnosis and blood transfusion: A case report and literature review. World J Clin Cases 2020; 8(19): 4595-4602 [PMID: 33083423 DOI: 10.12998/wjcc.v8.i19.4595] [Reference Citation Analysis]
7 Mathabire Rücker SC, Tayea A, Bitilinyu-Bangoh J, Bermúdez-Aza EH, Salumu L, Quiles IA, Szumilin E, Chirwa Z, Rick F, Maman D. High rates of hypertension, diabetes, elevated low-density lipoprotein cholesterol, and cardiovascular disease risk factors in HIV-infected patients in Malawi. AIDS 2018;32:253-60. [PMID: 29135581 DOI: 10.1097/QAD.0000000000001700] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
8 Osibogun O, Ogunmoroti O, Michos ED, Spatz ES, Olubajo B, Nasir K, Madhivanan P, Maziak W. HIV/HCV coinfection and the risk of cardiovascular disease: A meta-analysis. J Viral Hepat. 2017;24:998-1004. [PMID: 28502092 DOI: 10.1111/jvh.12725] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
9 Cuciureanu T, Chiriac S, Chiorescu M, Gîrleanu I, Trifan A. Chronic hepatitis C virus infection: a new modifiable cardio-metabolic risk factor? Clujul Med 2017;90:251-5. [PMID: 28781519 DOI: 10.15386/cjmed-793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Collins LF, Adekunle RO, Cartwright EJ. Metabolic Syndrome in HIV/HCV Co-infected Patients. Curr Treat Options Infect Dis 2019;11:351-71. [PMID: 32030090 DOI: 10.1007/s40506-019-00207-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cristelli MP, Trullàs JC, Cofán F, Rico N, Manzardo C, Ambrosioni J, Bedini JL, Moreno A, Diekmann F, Miro JM; CKD-H. Clinical Investigators. Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy. Braz J Infect Dis 2018;22:193-201. [PMID: 29782827 DOI: 10.1016/j.bjid.2018.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]